Welcome Message

It is a great pleasure to welcome you to the website of APAC (Asia Partnership Conference of Pharmaceutical Associations).
APAC is an industry-driven initiative with 14 R&D-based pharmaceutical associations in Asia that agree to work together to realize our mission: “To expedite the launch of innovative medicines for the people in Asia.”
Since its establishment in 2012, APAC has provided unique opportunities for constructive discussions among regulatory authorities, academia, and industries on timely topics to improve access to innovative medicines in Asia.
APAC working groups and task forces have evolved over time adjusting to the environmental changes. Now we have five active groups “Drug Discovery Alliance (DA)”, "Regulations and Approvals (RA)", "Manufacturing, Quality Control, and Supply (MQS)", " Digital Product Information/e-labeling", and "Universal Health Coverage in Asia (aUHC)", which have achieved high level of success in their efforts to promote collaboration and regulatory harmonization in each country.
The 14th APAC was held on April 22, 2025, in a hybrid face-to-face/online format. More than 600 people from not only industries but also regulatory authorities including the PMDA Asia Office established in 2024, government officials and academia in Asia participated. In this meeting, we learned the progress in microbiome research, necessity of establishing digital health platforms, reliance among regulatory authorities and GMP inspections, and the challenges to realize true UHC in Asia.
Dr. David Reddy, Director General of IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), also participated in this meeting and expressed his expectations for this unique and impactful platform.
The current global landscape is highly dynamic with significant events across various regions, and it is challenging for any single country to address globally shared issues. We believe that the activities of APAC, which already embody mutual country cooperation, will become increasingly important in the upcoming era to contribute to the health of the people in Asian countries.
We are committed to improving global health by further advancing multilateral and mutually beneficial dialogue, fostering “Co-creation” and collaboration among industry, government, academia, and patients, and by promoting innovation from Asia through APAC’s initiatives.



President

Asuka Miyabashira
President
Japan Pharmaceutical Manufacturers Association